Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$138.54 USD

138.54
1,169,708

+6.29 (4.76%)

Updated May 24, 2024 04:00 PM ET

After-Market: $138.53 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

DaVita Inc. [DVA]

Reports for Purchase

Showing records 261 - 280 ( 286 total )

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 261

10/18/2011

Company Report

Pages: 6

Preannouncement highlights strong fundamentals

Provider: FELTL & COMPANY

Analyst: WEIGHT M

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 262

10/14/2011

Company Report

Pages: 8

Price: 24.95

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 263

08/09/2011

Industry Report

Pages: 6

STOCKS WITH EXCEPTIONAL APPRECIATION OPPORTUNITY ONCE THE OVERALL MARKET STABILIZES

Provider: FELTL & COMPANY

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 264

08/05/2011

Company Report

Pages: 8

Price: 24.95

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 265

08/04/2011

Company Report

Pages: 7

Increasing estimates and price target on strong 2Q results

Provider: FELTL & COMPANY

Analyst: WEIGHT M

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 266

07/06/2011

Daily Note

Pages: 6

Top Ideas

Provider: FELTL & COMPANY

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 267

06/27/2011

Company Report

Pages: 6

FDA removes targeted Hb range for ESA?s, should drive further dosing declines

Provider: FELTL & COMPANY

Analyst: WEIGHT M

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 268

06/02/2011

Company Report

Pages: 10

Survey sees further opportunity to reduce patient costs; near-term margin expansion?

Provider: FELTL & COMPANY

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 269

06/02/2011

Company Report

Pages: 7

Price: 24.95

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 270

05/04/2011

Company Report

Pages: 7

1Q: Strong quarterly results; guidance sets floor for next two years

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 271

03/15/2011

Company Report

Pages: 7

Price: 24.95

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 272

02/11/2011

Company Report

Pages: 10

4Q: impressive cost reductions, we expect more in 2011, outlook better than ever

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 273

02/04/2011

Company Report

Pages: 9

DSI acquisition a solid deployment of excess capital

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 274

01/18/2011

Company Report

Pages: 11

Facility survey: Changes are underway and more diverse than expected

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 275

01/03/2011

Industry Report

Pages: 6

2011 Top Ideas.

Provider: FELTL & COMPANY

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 276

12/15/2010

Company Report

Pages: 7

Transition relief? It?s possible, but we remain skeptical

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 277

11/05/2010

Company Report

Pages: 10

3Q 2010 very good quarter overshadowed by international expansion plans, bundle prep

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 278

10/28/2010

Company Report

Pages: 10

3Q 2010 Preview:

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 279

10/21/2010

Company Report

Pages: 7

Price: 24.95

Company: DaVita Inc.

Industry: Medical - Outpatient and Home Healthcare

Record: 280

10/06/2010

Company Report

Pages: 6

Managed care survey indicates shift in dialysis provider contracts

Provider: FELTL & COMPANY

Analyst: HOERNEMANN J

Price: 25.00

Research Provided by a Third Party